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Accepted 15 May 2017; Published online xxxxAbstractObjectives: Assess (i) the quality of reporting and handling of missing data (MD) in palliative care trials, (ii) whether there are dif-
ferences in the reporting of criteria specified by the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement compared
with those not specified, and (iii) the association of the reporting of MD with journal impact factor and CONSORT endorsement status.
Study Design and Setting: Systematic review of palliative care randomized controlled trials. CENTRAL, MEDLINE, and EMBASE
(2009e2014) were searched.
Results: One hundred and eight trials (15,560 participants) were included. MD was incompletely reported and not handled in accor-
dance with current guidance. Reporting criteria specified by the CONSORT statement were better reported than those not specified (partic-
ipant flow, 69%; number of participants not included in the primary outcome analysis, 94%; and the reason for MD, 71%). However, MD in
items contributing to scale summaries (10%) and secondary outcomes (9%) were poorly reported, so the proportion of MD stated is likely to
be an underestimate. The reason for MD provided was unclear for 54% of participants and only 16% of trials with MD reported a MD
sensitivity analysis. The odds of reporting most of the MD and other risk of bias reporting criteria were increased as the journal impact
factor increased and in journals that endorsed the CONSORT statement.
Conclusion: Further development of the CONSORT MD reporting guidance is likely to improve the quality of reporting. Reporting
recommendations are provided.  2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Missing data (MD) present a significant risk to the
power, precision, generalizability, and validity of random-
ized controlled trial (RCT) findings. Transparent reporting
of MD is therefore crucial to the critical appraisal of
trial results by clinicians, patients, policymakers, journal-
ists, and researchers [1,2]. Palliative care trials inConflict of interest: None to report.
* Corresponding author. Tel.: þ44-870-1245500; fax: þ44-019-
04321696.
E-mail address: jamillahussain05@gmail.com (J.A. Hussain).
http://dx.doi.org/10.1016/j.jclinepi.2017.05.009
0895-4356/ 2017 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).particular have large amounts of MD, as well as differen-
tial rates and reasons of missingness across trial arms that
potentially introduce bias [3].
To strengthen the reporting standards of MD in trial re-
ports, the 2010 Consolidated Standards of Reporting Trials
(CONSORT) statement highlights the potential impact of
MD on the validity of intention-to-treat analyses [4]. The
guidance recommends using a participant flow diagram that
demonstrates post-randomization losses and exclusions
(with reasons) and to report the number of participants
included in each analysis [4]. It does not however provide
specific guidance on how to report methods to handle
MD, assumptions about the MD mechanism, and MDess article under the CC BY-NC-ND license (http://creativecommons.org/
Clinical Epidemiology - (2017) -What is new?
Key findings
 Missing data (MD) in palliative care trials are not
reported and handled in a clear, complete, and
transparent manner.
 Criteria specified by the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statement
were better reported than those specified by other
reporting guidelines.
 The odds of reporting most MD and other risk of
bias reporting criteria were increased as the journal
impact factor doubled and in journals that endorsed
the CONSORT statement.
What this adds to what was known?
 Assessment of the risk MD pose to the power, pre-
cision, generalisability and validity of trial findings
is substantially hindered by poor reporting.
What is the implication and what should change
now?
 Further development of the CONSORT MD report-
ing guidance would potentially strengthen report-
ing standards. Reporting recommendations are
provided for published trial reports.
sensitivity analyses. It could be argued that the application
of the general CONSORT principles would encourage the
reporting of all these [5], but it is unknown if this is the
case.
Guidelines that specify additional criteria for reporting
MD are available. Akl et al. [2] conducted a systematic
survey of literature to identify recommendations for report-
ing MD in RCTs. They selected 13 articles including the
CONSORT 2010 statement for parallel trials [6] and the
CONSORT extensions for patient-reported outcomes [7],
harm [8], and cluster trials [9]. From these recommenda-
tions, they provided reporting guidance covering the
proportion, reasons, patterns, analytical methods, and
interpretation of MD [2].
Several groups have provided further guidance on the
prevention and handling of MD, including recommenda-
tions for reporting [1,10e14]. The Methods Of Researching
End of Life Care collaboration proposed that palliative care
trials should specifically report the proportion of attrition
because of death and illness [12]. Trialists are also encour-
aged to report comparisons of baseline characteristics
between trial arms of participants with observed data and
missing values to assess the effect of MD on the balance
of trial arms for measured participant characteristics
[13] - although it is important to note that trials are not
2 J.A. Hussain et al. / Journal ofnecessarily powered for such analyses, and the absence of
differences does not guarantee lack of bias.
No single method of accommodating MD is recommended
for all trials [15]; however, principled methods, which do not
attempt to replace the missing values directly but instead
combine information from observed data with explicit as-
sumptions about the MD, are advocated [16]. These methods,
such as multiple imputation, generate statistical information
about the MD and/or its mechanism, thus taking account of
the uncertainty in estimating the missing values
[10,11,16,17]. In contrast, ad-hoc methods (e.g., complete
case analysis [CCA] and last observation carried forward)
either exclude participants with MD or impute a single value
for the MD and then treat the data set as if it were the fully
observed data [16]. These are generally discouraged as they
rely on strong assumptions that are often unlikely to be true.
CCA in particular is inefficient as it ignores the information
that is typically provided by incomplete cases [16]. However,
all methods to analyze MD are based on assumptions that
cannot be verified from the partially observed data; therefore,
conducting MD sensitivity analyses that explore the sensitivity
of the results to different assumptions about the missingness
mechanism is strongly recommended [11,18].
An important consideration, especially in palliative care,
is that data unmeasured because of death should not be
considered as missing but rather as undefined [19]. Such
data are referred to as ‘truncated due to death’ to distinguish
them from MD in living participants [20]. The handling of
truncated data presents a different problem to MD in those
alive, and a distinction should be made between the methods
to handle such data. This is a developing area of research,
and several methods, taking different approaches to condi-
tioning on survival, are advocated [20].
The compliance of palliative care trial reports with guid-
ance on MD reporting and handling is unknown. Given the
extent and risk of bias posed by MD in palliative care trials,
clear reporting should be given particular attention in this
field. Two reviews of trials across disciplines published in
high-impact medical journals found that 45% of trials used
CCA as their primary analysis [21,22], and a MD sensi-
tivity analysis was reported in 21% [21] and 35% [22],
respectively. These reviews however assessed a limited
number of criteria relating to MD reporting and primarily
focused on the amount and handling of MD, without specif-
ically differentiating between MD in those alive and trun-
cated data due to death.
Furthermore, it is also important to understand which
factors are associated with the implementation of MD
reporting guidance. A Cochrane review of whether journal
endorsement of CONSORT affected the completeness of
RCT reports concluded that ‘despite relative improvements
when CONSORT is endorsed by journals, the completeness
of reporting remains suboptimal’ [23]. Moreover, a review
that compared methodological characteristics of RCTs pub-
lished in higher vs. lower impact clinical journals found
that loss to follow-up was reported more commonly in
3J.A. Hussain et al. / Journal of Clinical Epidemiology - (2017) -higher impact journals (80% vs. 68%) [24]. Assessment of
the effect of journal impact factor (JIF) and CONSORT
endorsement status on the quality of MD reporting will
be a useful first step to understand how implementation
of MD reporting guidance can be optimized.
This systematic review of RCTs evaluating palliative in-
terventions in patients with advanced life-limiting illness
aimed to assess (1) to what extent MD are reported and
handled in accordance with current reporting guidance,
(2) whether quality of reporting differs between MD
criteria specified by the CONSORT 2010 statement and
MD criteria not specified by CONSORT, and (3) whether
JIF and CONSORT endorsement status are associated with
the quality of MD reporting and how this compared to the
reporting of other methodological risks of bias such as
allocation concealment and blinding.2. Materials and methods
This systematic review was done as part of a larger project.
Detailed description of the methods is available elsewhere [3].
2.1. Eligibility criteria
Eligible studies were RCTs that included participants
with an advanced life-limiting illness with no possibility
of remission and tested a palliative intervention that aimed
to improve quality of life rather than modify the disease
process or improve survival. Outcomes were patient
reported and included among others symptom control,
psychospiritual, and quality of life outcomes. Trials pub-
lished between January 2009 and April 2014 were included
to capture current reporting practice that overlaps with the
publication of the CONSORT 2010 statement. There were
no language restrictions.
2.2. Search strategy and study selection
CENTRAL, OVID MEDLINE, and EMBASE (January
2009eApril 2014) were searched by an information
specialist who combined the validated Cochrane PaPaS
palliative care search strategy [25] and the sensitivity maxi-
mizing Cochrane Highly Sensitive Search Strategy for iden-
tifying RCTs in MEDLINE [26] (Appendix A; last searched
May 2014; see on the journal’s Web site at www.elsevier.
com). A random sample of 100 trials was initially chosen
from those identified by the search to obtain a representative
rather than exhaustive sample for this methodological
review of a broad subject area such as palliative care. How-
ever, a large proportion of the studies screened were not
eligible for inclusion, and consequently, all the identified
trials were screened to identify the desired number of trials.
Two reviewers independently conducted the screening and
selection of trials. Any discrepancies were discussed in a
meeting, and arbitration by a third reviewer was not
required. Authors were only contacted if there wasinsufficient information to make a decision about inclusion
based on the published article and supplementary material.
2.3. MD criteria
In this review, MD are defined as observations that were
intended to be made but were not [16]. This included MD
that occur at different levels: (1) unit-level MD, where the
participant was not available to provide data and (2) item-
level MD, where individual questions from questionnaires,
surveys, or scale measures are missing; and with different
patterns: (1) monotone MD, where the participant with-
draws completely from the trial and provides no further data
and (2) intermittent MD, where the participant does not pro-
vide data at particular time points while remaining in the
trial. The MD reporting criteria are listed in Table 1, and
the definitions used to determine whether the criteria were
successfully reported are presented in Appendix B (see on
the journal’s Web site at www.elsevier.com).
2.4. Data extraction
Duplicate data extraction was conducted. A data extrac-
tion form that combined the MD reporting recommenda-
tions of the CONSORT 2010 statement [27] with those
by other groups was developed and piloted [1,2,10e13].
Although further MD reporting guidance is provided in
some of the extensions of the CONSORT statement
[7e9], as MD are ubiquitous across trial designs, this
review differentiated between the CONSORT 2010 recom-
mendations for two-group parallel trialsdwhich provide
guidance for the reporting of all RCTs [6]dand those not
specified in this guidance. If more than one primary
outcome was reported or no primary outcome was speci-
fied, the first outcome reported was considered to be the
primary outcome. For repeated measures, where the pri-
mary end point was not clearly specified, the final observa-
tion was taken as the primary end point. The reporting of
other methodological risks of bias (random sequence gener-
ation, allocation concealment, and blinding) was also ex-
tracted, as were the reported reasons for MD and methods
used to handle MD.
2.5. Data synthesis and analysis
The proportion of trials that reported each criterion and
the reported reasons and methods to handle MD were tabu-
lated. The relationship of the quality of reporting MD and
other methodological risks of bias with the JIF (as reported
by Thomson Reuters Journal Citation Report 2014 [28]) and
with the CONSORTendorsement status of the journal (deter-
mined on July 7, 2015 in accordance with the list reported on
the CONSORT Web site [29]) was assessed using logistic
regression with either log-transformed JIF or endorsement
status as the independent variable and the reporting criterion
as the dependent variable. To reduce the risk of multiple
testing, a priori it was decided to test only those criteria that
Table 1. Quality of MD reporting according to current reporting guidance
Reporting category MD reporting criterion Proportion of trials reporting criteria
Proportion of MD Account for all participants who enter the studya 69% (75/108)
Report number of participants not included in the primary
outcome analysisa
94% (101/108)
Report number of participants with MD in each arm in the
primary outcome analysisa,b
87% (85/98)b
Report amount of item-levelc MD in the primary outcome analysis 10% (5/50)d
Report MD trend over time for primary outcomes measured repeatedly All time points: 7% (5/69)
Some time points: 48% (33/69)
Report amount of MD for secondary outcomes For all: 9% (9/99)e
For some: 18% (18/99)
Reasons for MD Report reason for MDa 71% (66/93)f
Report amount of MD because of death 65% (60/93)f
Report amount of MD because of illness or disease progression 46% (43/93)f
Minimizing MD Report plans to minimize MD 27% (29/108)
Risk of bias posed by MD Report comparison of baseline characteristics of those with observed data 6% (6/93)f
Report comparison of baseline characteristics of those with MD 0%
Justification of MD
analytical approach
Report assumed mechanism of MDg 3% (3/108)
Report criteria for MNAR (informative MD) 1% (1/108)
Report pattern of missingness 0%
Compare baseline characteristics of those with and without MD 13% (12/93)e
Statistical methods
to handle MD
Report methods used to handle MD 48% (45/93)e
Report methods used to handle truncated data because of death 5% (3/60)h
Report MD sensitivity analyses 16% (15/93)f
Report any changes to the planned MD analysis 0%
Impact of MD on
the trial findings
Discuss impact of MD on the interpretation of findings 46% (43/93)f
Abbreviations: MD, missing data; MNAR, missing not at random.
a The Consolidated Standards of Reporting Trials 2010 statement recommendation.
b In nonecrossover trials only.
c For example, missing individual questions from a questionnaire, survey, or scale.
d In 50 trials, the primary outcome was a scale summary.
e In trials that measured secondary outcomes only.
f About 15 trials reported no MD and therefore were excluded.
g For example, missing completely at random, missing at random, or MNAR.
h In trials that reported data was truncated due to death.
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MD to test only if any reason was provided. Some journals
published a number of trials, and such clustering was taken
into account using the cluster command in STATA (Stata-
Corp LLC, College Station, Texas), version 13 [30]. All an-
alyses were conducted using STATA, version 13 [31]. The
level of statistical significance was set at 5% for all analyses.3. Results
The search yielded 1,923 identified references that were
screened; 179 articles were read in full, and 108 were
included in the review (Fig. 1). The full texts for four arti-
cles were not available (Appendix C; see on the journal’s
Web site at www.elsevier.com), and two included articles
were translated from French and Chinese to English. Study
demographics are presented in Appendix D (see on the jour-
nal’s Web site at www.elsevier.com).3.1. Quality of MD reporting
Table 1 presents the proportion of included trials that
reported the MD criteria specified by current guidance.3.1.1. Proportion of MD
Sixty-nine percent of trials (75 of 108) accounted for
all participants who entered the study, 94% (101 of 108)
reported the number of participants not included in the
primary outcome analysis, and 87% of nonecrossover
trials (85 of 98) reported the number of participants with
MD in each arm. Fourteen percent (15 of 108) of trials re-
ported that there were no MD. Of trials reporting a scale
summary, only 10% (5 of 50) reported item-level MD.
When the primary outcome was measured repeatedly,
MD at each time point was reported by 7% (5 of 69) of
trials. Only 9% (9 of 99) of trials reported the amount
of MD for all secondary outcomes. However, for 59%
(58 of 99), the proportion could be assumed to be the
same as for the primary outcome as the reason for MD
seemed to relate to unit nonresponse (i.e., the participant
was missing) through the use of terms such as attrition or
withdrawaldalthough the definition of these terms was
not specified.3.1.2. Reasons for MD
Of the trials that reported MD (n 5 93), 71% (66 of 93)
reported the reason for MD for all participants, 16% (15
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Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses study flow diagram.
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any reasons, and in 4% (4 of 93), it was unclear. In this
palliative care sample, 65% (60 of 93) of trials reported
the proportion of MD because of death and 46% (43 of
93) the proportion due to illness. For more than half of
all the participants with MD, the reported reason for miss-
ingness was described as ‘loss to follow-up’ or ‘with-
drawal’ with no further qualification of how these were
defined or description of the underlying reason for the
‘loss to follow-up’ or ‘withdrawal’ (Table 2). Only two
trials specified that they differentiated between with-
drawal from the trial and withdrawal from the interven-
tion or control while remaining under follow-up.3.1.3. Minimizing MD
Twenty-seven percent (29 of 108) of trials reported an
attempt to minimize MD during the design or conduct
phase of the trial. The most common reported method
was the exclusion of participants with an expected poorprognosis or poor performance status. Other methods
included limiting the number of outcomes and frequency
of data collection, sending telephone/mail reminders, flexi-
bility in the protocol, and monetary incentives.
3.1.4. Risk of bias posed by MD
Six trials that reported MD compared baseline character-
istics of participants with observed data; two conducted a
significance test, of which one found evidence of a differ-
ence between trials arms at the 5% significance level. No
trials compared the characteristics of those with MD in
different trial arms.
3.1.5. Justification of MD analytical approach
Three trials reported in the Methods section that they
assumed MD were missing at random [32e34]. One trial
also specified the missing not at random (MNAR) assump-
tions that formed part of their sensitivity analysis [35]. No
trials specifically reported whether the reasons for
Table 2. Reported reasons for MD (total number of participants with
MD 5 5,903)
Reason % (Number of participants)
Death 18 (1,063)
Illness/disease progression 6 (342)
Adverse effects/events 2 (112)
Unclassifieda 53 (3,158)
Otherb 6 (371)
Not reported 15 (856)
Abbreviation: MD, missing data.
a Described as loss to follow-up or withdrawal with no further de-
tails of the underlying reason.
b These included, for example, reported exclusions from the anal-
ysis because the ‘treatment failed’ or there was a ‘protocol violation’,
as well as ‘researcher error’, ‘response not evaluable’, and ‘care trans-
ferred to another setting’.
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related to the value of the outcome that was missing.
Twelve trials reported a comparison of the baseline charac-
teristics of those with observed and MD; and in seven of
these, there was a statistically significant difference in at
least one characteristic.
3.1.6. Statistical methods to handle MD
The method of handling MD was reported in 48% (45 of
93) of trials with MD. In a further 37% (34 of 93) of trials,
the method was not reported, but the text and tables indi-
cated that only complete cases were included in the final
analysis. In 15% (14 of 93) of trials, the method of analysis
could not be deduced, and it was assumed that CCA was
used as this is the default method in most statistical pack-
ages, and it is likely that if other methods to handle MD
were used, these would have been reported. Of the trials
that reported MD, 78% (73 of 93) used only one method
of analysis: 60% (56 of 93) used or were assumed to have
used CCA, 3% (3 of 93) other ad-hoc methods, and 15%
(14 of 93) principled methods. Fourteen percent (13 of
93) of trials used more than one ad-hoc method, and 8%
(7 of 93) used both principled and ad-hoc methods. Only
three trials [33,36,37] reported that they handled truncated
data due to death differently or separately to MD for other
reasons, with only one using a recommended method that
accounts for participants who died [37].
Sixteen percent (15 of 93) of trials used more than one
method to analyze MD and reported a MD sensitivity anal-
ysis. Of these, 12 reported an ad-hoc method of accommo-
dating MD as the primary analysis, and 11 used CCA and
one other method of analysis.
3.1.7. Impact of MD on trial findings
The potential impact of MD on the interpretation of the
trial results was discussed in 46% (43 of 93) of trials with
MD. This was most often described in the limitations sec-
tions of the article, and few articles specifically discussed
the potential for MD to bias the treatment effect estimate
[37e49].3.2. Differences in quality of reporting between criteria
The four MD reporting criteria specified in the
CONSORT 2010 statement were reported in more than
69% of trials (range, 69e94%) (Table 1). Additional
criteria from other guidelines were less well reported
(range, 0e65%), with comparison of baseline characteris-
tics of those with MD, pattern of missingness, and changes
to methods of handling MD not reported in any of the
selected trials.
3.3. Reporting of MD according to JIF and CONSORT
endorsement status
The median JIF of the included trials was 2.8 (interquar-
tile range, 1.8e4.5; range, 0e55.9), and 41 trials were pub-
lished in journals that endorsed the CONSORT statement.
Univariable logistic regressions (Table 3) demonstrated that
as the JIF doubled the odds of reporting all but the reasons
for MD were increased. This was similarly the case for
trials reported in journals that endorsed the CONSORT
statement, except that the odds ratio for the reporting of
plans to minimize MD was 1.00. At the 5% significance
level, the odds of accounting for all participants, reporting
the number of participants not included in the analysis,
comparing baseline characteristics of those with and
without MD, reporting method of handling MD, and report-
ing allocation concealment were statistically significantly
increased as the JIF doubled. Journals that endorsed the
CONSORT statement as of July 2015 only had statistically
significantly higher odds of reporting both the method of
handling MD and an MD sensitivity analysis (Table 3).4. Discussion
MD in palliative care RCTs are not reported in a clear,
complete, and transparent manner. Criteria specified by
the CONSORT statement were better reported. However,
item-level and secondary outcome MD were poorly re-
ported, thus the proportion of MD reported in published ar-
ticles is likely to be an underestimate. The reported reasons
for MD were unclassified in more than half of the partici-
pants and the risk of bias posed by MD and justification
of the analytical approach were the least well reported cat-
egories. Guidance on methods to handle MD was poorly
implemented, and only one trial reported the use of a rec-
ommended method to handle data truncated by death.
The odds of reporting most of the MD and other risk of bias
criteria tested were increased as the JIF increased and in
journals that endorsed the CONSORT statement.
One possible explanation for poorer reporting of MD
criteria not specifically recommended by CONSORT is that
the journal word count requirements restrict what could be
stated. However, a review of MD in health technology
assessment monographs, which do not have a word count
limit, found MD was rarely discussed and that MD
Table 3. Univariable logistic regressions of MD reporting criteria and other risk of bias CONSORT reporting criteria with JIF and whether the journal
endorsed the CONSORT statement
Reporting criterion
JIF CONSORT endorsement status
Odds ratio per doubling JIF P
95% Confidence
interval Odds ratio P
95% Confidence
interval
MD reporting criteria
Account for all participantsa 1.54 0.001 1.20e1.97 2.46 0.1 0.73e8.23
Report number of participants not
included in the primary outcome
analysisa
1.39 0.001 1.15e1.69 1.20 0.8 0.31e4.70
Report reasons for MDa,b 0.88 0.5 0.63e1.23 0.65 0.5 0.20e2.17
Report plans to minimize MD 1.16 0.17 0.94e1.42 1.00 1.00 0.40e2.49
Compare baseline characteristics of
participants with and without MD
1.50 !0.001 1.20e1.87 1.11 0.83 0.42e2.92
Report methods used to handle MD 1.40 0.002 1.13e1.73 2.53 0.03 1.08e5.94
Report MD sensitivity analyses 1.20 0.4 0.81e1.80 3.48 0.03 1.15e10.50
Discuss impact of MD on the
interpretation of findings
1.14 0.2 0.93e1.41 1.85 0.1 0.85e4.04
Other CONSORT 2010 risk of bias reporting criteria
Report method of sequence generationa 1.09 0.2 0.94e1.26 1.79 0.2 0.79e4.03
Report method of allocation sequence
concealmenta
1.29 0.01 1.06e1.57 2.03 0.2 0.36e6.55
Report blinding participants &
personnela
1.09 0.2 0.96e1.25 1.32 0.6 0.51e3.41
Report method of blinding outcome
assessmenta
1.04 0.5 0.91e1.19 1.41 0.5 0.55e3.62
Abbreviations: MD, missing data; CONSORT, the Consolidated Standards of Reporting Trials; JIF, journal impact factor.
a CONSORT 2010 recommendation.
b Assessed as whether they reported any reasons for MD.
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This review preceded the CONSORT 2010 statement, which
has addressed MD somewhat, but our study illustrates that
further development of the CONSORT MD guidance could
be a key step to the improvement of MD reporting.
The results of our review are consistent with a Cochrane
review of the reporting of criteria recommended in the
1996 and 2001 CONSORT statements. This review found
allocation concealment and the method for sequence genera-
tion to be statistically more likely to be reported in
CONSORT-endorsing journals [51]. Inconsistencies in
reporting may be explained partly by a study that found that
only 41% of journal editors made the CONSORT statement
part of their peer-review process, 47% made it part of their
editorial process [52], and only 38% of journals mentioned
CONSORT in their instructions to authors [52]. As the
median JIF for the palliative care trials included in this
review was only 2.8 and fewer than half of the trials were
published in journals that endorsed the CONSORT statement,
it is important to develop a better understanding of how to
optimize implementation of the CONSORT statement across
journals, so that future developments in the reporting of MD
guidance can improve RCT reporting practice.
It is important that reasons for MD are reported. This is
crucial to the assessment of how MD can be minimized,
whether MD introduces bias through differential reasons
for missingness across trial arms, and the most appropriate
methods to handle MD. This review demonstrated that
terms such as withdrawal and loss to follow-up are oftenused without being defined. Definitions of these terms vary
in the literature, and there is no specification that the under-
lying reasons for withdrawal or loss to follow-up should be
reported [53e55]. Future guidance on MD reporting should
highlight this and recommend that the underlying reason is
reported and that any ambiguous terms are defined.
Choice of methods to handle MD was also reported
inadequately. CCA was used as the sole method to analyze
MD in 60% of trials, although a large proportion of MD in
this population is expected to be due to death and disease
progression and therefore potentially cause bias in a
CCA. Only 16% of trials conducted any MD sensitivity
analysis with most not using a principled method for the
primary analysis and only one study reporting the sensi-
tivity of the effect estimate to an MNAR assumption. This
is worse than the findings of two previous reviews of trials
published in high-impact medical journals [21,22]. Our re-
view provides further evidence that better implementation
of guidance to handle MD is required and importantly in-
cludes trials published across journals with a range of
impact factors. Although CONSORT does not aim to make
recommendations about how trials should be analyzed [6],
it does indirectly affect trial analysis as transparent report-
ing can highlight gaps in implementation [6]. Therefore, we
recommend that future guidance includes a specific require-
ment to report how MD are handled for both participants
who are alive and those whose data were truncated by death
(if applicable), with justification of the methods used, and
an MD sensitivity analysis.
1Missingness mechan
*These criteria could be provided as part of supplementary material available on-line
ism relates to Little and Rubin’s taxonomy: missing completely at random 
(MCAR), missing at random (MAR) and missing not at random (MNAR).
Methods section:
1. Report the justification of the missing data analytical approach including all of the following:
a. Any assumptions about the missing data mechanism1 with justification.
b. What analyses will be performed to support assumptions about the missingness mechanism. For 
example, comparison of variables according to whether the partially observed variable of interest was 
missing may shed light on the credibility of the MAR assumption. 
c. *How the assumed missingness mechanism and any relevant features of the data such as pattern of 
missingness would influence the choice of method(s) to handle missing data and missing data 
sensitivity analyses.
d. Details of the statistical methods used to handle missing data.
e. How truncated data due to death will be handled and justification of method(s) (if applicable)2.
Results section:
2.  Report the following measures of the amount of missing data 
a. For each outcome: number of participants in each arm with missing data (unit-level missing data).
b. For outcomes that are scale summaries: amount of item-level missing data, for example the number
of participants in each arm with some items reported and some items missing, and/or the proportion of 
item-level missing data.
c. For repeated outcomes: number of participants in each arm with missing data at each time-point.
3. Reasons for missing data in each arm, with enough detail that the reported reason can be used to reduce 
the uncertainty about the potential underlying mechanism of missing data. If terms such as loss to follow
up or withdrawal are used, these must be defined and the underlying reason specified.
4. Comparison of the baseline characteristics of those included in the analysis (if participants are excluded 
from the analysis post-randomisation).
5. *Results of investigations of the missingness mechanism and/or pattern, and whether these led to 
changes to the choice of the primary method3 to handle missing data.
6. *Missing data sensitivity analyses results including analyses based on plausible missing not at random 
assumptions if appropriate.
Discussion section:
7. Impact of missing data on the interpretation of findings, including effect on validity and 
generalisability.
2Not specifically recommended in previous reporting guidance but considered important for the 
assessment of whether appropriate methods to analyse data were used. 
3The primary analysis should involve a principled method to accommodate missing data that is based 
on plausible assumptions about the missingness mechanism and takes into account the uncertainty in 
estimating the missing values.
Fig. 2. Recommendations for reporting missing data.
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review was submitted for publication to PROSPERO
(August 2014); however, as this was a methodology review
with no direct health-related outcomes, it did not meet the
eligibility criteria. It was then submitted to the Cochrane
Methodology Review register (August 2014); however, this
was not undergoing updates at this time because of resource
constraints. In view of the time constraint to commence the
review, the protocol was not submitted for external peer
review although it was reviewed by all authors of this
article and the director of a local trials unit. Because of
the evolving nature of palliative care, identification of
relevant literature can be difficult, and some trials may have
been missed. Four identified trials could not be included as
the full texts could not be retrieved. It was decided a-priori
that data reported elsewhere would not be assessed because
clinicians, researchers, and policymakers often rely solely
on the peer-reviewed journal article to make a judgment
about the methodological risks of bias, although supple-
mentary online material was reviewed. Finally, it was not
possible to determine retrospectively whether all the jour-
nals that endorsed the CONSORT statement did so specif-
ically at the time of publication of each study.
This systematic review is the first to assess how well
MD are reported according to current guidance. We have
used these findings to provide further reporting recom-
mendations that build on those proposed by the CON-
SORT 2010 statement [6] and other groups
[1,2,10e14,20,56] (Fig. 2). Our recommendations focus
specifically on what should be reported in trial reports
rather than on which methods should be used to minimize
and handle MD, in keeping with the scope of the CON-
SORT statement. The rigorous methods, evolving nature,
and wide recognition and endorsement of the CONSORT
statement [6] make it ideally placed to facilitate better re-
porting of MD. Incorporation of these recommendations
into future CONSORT statements will potentially improve
the awareness of journal editors, peer reviewers, re-
searchers, clinicians, patients, journalists and policy-
makers on what should be reported with regard to MD
to enable a more accurate assessment of the risk of bias
posed; the quality of reporting; and the quality of trial
conduct and handling of MD. Further research is required
to understand how to improve the implementation of re-
porting guidance.Acknowledgments
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